TW200639156A - New compounds - Google Patents

New compounds

Info

Publication number
TW200639156A
TW200639156A TW095104480A TW95104480A TW200639156A TW 200639156 A TW200639156 A TW 200639156A TW 095104480 A TW095104480 A TW 095104480A TW 95104480 A TW95104480 A TW 95104480A TW 200639156 A TW200639156 A TW 200639156A
Authority
TW
Taiwan
Prior art keywords
new compounds
therapy
formula
preparation
pharmaceutically acceptable
Prior art date
Application number
TW095104480A
Other languages
Chinese (zh)
Inventor
Andrew Baxter
Sarah King
Austen Pimm
Chris Luckhurst
Mark Furber
James Reuberson
Ian Millichip
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200639156A publication Critical patent/TW200639156A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The invention provides compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein A, R1, R2 and R3 are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.
TW095104480A 2005-02-11 2006-02-10 New compounds TW200639156A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0500336 2005-02-11

Publications (1)

Publication Number Publication Date
TW200639156A true TW200639156A (en) 2006-11-16

Family

ID=36793310

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095104480A TW200639156A (en) 2005-02-11 2006-02-10 New compounds

Country Status (4)

Country Link
AR (1) AR052900A1 (en)
TW (1) TW200639156A (en)
UY (1) UY29370A1 (en)
WO (1) WO2006085815A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078322A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
JP6929792B2 (en) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド Sulfonylureas and related compounds and their use
AU2017416068A1 (en) 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
RS62910B1 (en) 2017-07-07 2022-03-31 Inflazome Ltd Novel sulfonamide carboxamide compounds
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
RU2020110366A (en) * 2017-08-15 2021-09-16 Инфлазоум Лимитед NEW COMPOUNDS OF SULFONAMIDE CARBOXAMIDES
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Novel sulfonamide carboxamide compounds
RU2020110219A (en) * 2017-08-15 2021-09-17 Инфлазоум Лимитед SULFONYLUREAS AND SULFONYLTHIUREAS AS NLRP3 INHIBITORS
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
CA3071145A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (en) * 2017-11-09 2020-06-19 英夫拉索姆有限公司 Novel sulfonamide carboxamide compounds
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885890A1 (en) * 1996-02-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
EP1441732A2 (en) * 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
CL2004000545A1 (en) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B USE OF AN ANTAGONIST OF ALDOSTERONE RECEPTORS AND AN ENDOTHELINE RECEIVER ANTAGONIST FOR THE TREATMENT OR PROFILAXIS OF A PATHOLOGICAL CONDITION RELATED TO HYPERTENSION, RENAL DYSFUNCTION, INSULINOPATHY AND CARDIOVASCUL DISEASES

Also Published As

Publication number Publication date
UY29370A1 (en) 2006-10-02
WO2006085815A1 (en) 2006-08-17
AR052900A1 (en) 2007-04-11

Similar Documents

Publication Publication Date Title
TW200639156A (en) New compounds
TW200613243A (en) Novel compounds
TW200616995A (en) Novel compounds
TW200801003A (en) Novel compounds
TW200626553A (en) Novel compounds
TW200800999A (en) Novel compounds
TW200745114A (en) Novel compounds
TW200745084A (en) Novel compounds
TW200508214A (en) Novel compounds
SE0202539D0 (en) Compounds
TW200738659A (en) Novel compounds
SE0200920D0 (en) Novel compounds
SG170069A1 (en) Quinoline derivatives
TW200621762A (en) Novel compounds
MX2010009022A (en) 16 alpha, 17 alpa-acetal glucocorticosteroidal derivatives and their use.
TW200640908A (en) Chemical compounds
TW200605888A (en) Novel compounds
TW200700392A (en) Novel compounds
MXPA05008690A (en) Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them.
MY145647A (en) (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states)
TW200635917A (en) Novel compounds
TW200833670A (en) Novel compounds 569
TW200745122A (en) New compounds I
MX2009006010A (en) Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases.
TW200635916A (en) Compounds